Dopamine agonists for preventing ovarian hyperstimulation syndrome-Reference-Cited by-同舟云学术

Dopamine agonists for preventing ovarian hyperstimulation syndrome

Published:2021-04-14 Issue:4 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Tang Huilin¹,Mourad Selma M.²,Wang Aihua³,Zhai Suo-Di⁴,Hart Roger J⁵

Affiliation:

1. Institute for Drug Evaluation; Peking University Health Science Center; Beijing China

2. Radboud University Medical Centre; Nijmegen Netherlands

3. Department of Pharmacy; Beijing Obstetrics and Gynecology Hospital, Capital Medical University; Beijing China

4. Department of Pharmacy, Therapeutic Drug Monitoring and Clinical Toxicology Center of Peking University; Peking University Third Hospital; Beijing China

5. School of Women's and Infants' Health; The University of Western Australia, King Edward Memorial Hospital and Fertility Specialists of Western Australia; Subiaco, Perth Australia

Publisher

Wiley

Subject

Pharmacology (medical)

Reference111 articles.

1. Role of quinagolide (Norprolac) in preventing ovarian hyperstimulation syndrome (OHSS) in high risk intracytoplasmic sperm injection (ICSI) patients;Alhalabi;Fertility and Sterility,2010

2. Quinagolide reduces OHSS in high risk ICSI patients;Alhalabi;Human Reproduction,2011

3. Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial;El-Shaer;Human Reproduction,2019

4. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients;Alvarez;Human Reproduction,2006

5. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction;Alvarez;Journal of Clinical Endocrinology and Metabolism,2007

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The HERA (Hyper-response Risk Assessment) Delphi consensus for the management of hyper-responders in in vitro fertilization;Journal of Assisted Reproduction and Genetics;2023-09-15

2. Interventions to prevent or reduce the incidence and severity of ovarian hyperstimulation syndrome: a systematic umbrella review of the best clinical evidence;Reproductive Biology and Endocrinology;2023-07-21

3. Incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders after gonadotropin-releasing hormone (GnRH) agonist trigger in “freeze-all” approach;Gynecological Endocrinology;2023-05-08

4. Intracranial and Extracranial Progression and Their Correlation With Overall Survival After Stereotactic Radiosurgery in a Multi-institutional Cohort With Brain Metastases;JAMA Network Open;2023-04-26

5. What are the effects of dopamine agonists on ovarian hyperstimulation syndrome (OHSS) and pregnancy outcomes in women undergoing assisted reproductive technology (ART) therapy?;Cochrane Clinical Answers;2021-05-26